GLP-1 acts as follows: Triggers insulin release from the pancreas, to regulate blood sugar Blocks glucagon secretion: glucagon is a natural hormone which acts to release glucose into the bloodstream Increases glucose uptake into muscles Slows stomach emptying: Slower digestion means you stay full for longer, and your body releases sugar into the bloodstream more slowly Affects the area in your brain that processes hunger (the hypothalamus), making you feel full more quickly So, where are we now, in 2025, with obesity and GLP-1 agonist medications
3,19,20,21 As a consequence, abnormal GH secretion has the potential to impact multiple tissues and organs
demonstrated improvements in endothelial function markers in older adults following glutathione repletion [10][21]
That logic is self-defeating: If GLP-1s really are worth that much to Americans health, then they are worth paying the market price and worth enough that other suppliers will want to introduce competitors to meet Americans needs
These products are not for human consumption or therapeutic use
The experience that Ive had with my patients points me to think there is something more physiological, neurobiological going on that the medication addresses. People who binge as a coping mechanism may also find that anxiety gets worse once appetite is suppressed
